内镜下括约肌切开预防远端恶性胆道梗阻自膨式金属支架置入后ERCP术后胰腺炎(SPHINX):多中心随机对照试验
这项多中心随机优效性试验在17家医院纳入297例疑似远端恶性胆道梗阻患者,于ERCP中随机接受内镜下括约肌切开或不切开后再置入全覆膜自膨式金属支架。括约肌切开组PEP发生26例(17%),对照组30例(21%),相对风险0.78(95%CI 0.49至1.26,p=0.37),因无效提前终止,认为括约肌切开不优于不切开。
要点
- 括约肌切开组PEP 26例(17%)vs 对照组30例(21%),相对风险0.78(95%CI 0.49至1.26,p=0.37)。
- 出血、穿孔、胆管炎、胆囊炎及30天死亡率两组无显著差异。
- 研究因无效提前终止,证据不足以推荐置入全覆膜自膨式金属支架前常规行内镜下括约肌切开。
核心结论
- 该试验发现,在远端恶性胆道梗阻患者中,内镜下括约肌切开在降低ERCP术后胰腺炎方面不优于不切开。
- 因此,证据不足以推荐在全覆膜自膨式金属支架置入前常规行内镜下括约肌切开。
研究设计与样本
- 多中心、随机、优效性试验,在17家医院开展,纳入疑似远端恶性胆道梗阻患者。
- 患者在ERCP中随机接受内镜下括约肌切开(括约肌切开组)或不切开(对照组)后再置入全覆膜自膨式金属支架。
- 主要结局为30天内ERCP术后胰腺炎,次要结局包括操作相关并发症和30天死亡率。
- 在50%患者(n=259)完成随访后进行中期分析。
- 2016年5月至2023年6月间,意向性治疗分析纳入297例患者,括约肌切开组156例,对照组141例。
主要发现
- 中期分析后,研究因无效提前终止。
- ERCP术后胰腺炎两组无差异,括约肌切开组26例(17%)vs 对照组30例(21%)(相对风险0.78,95%CI 0.49至1.26,p=0.37)。
- 出血、穿孔、胆管炎、胆囊炎或30天死亡率均无显著差异。
临床怎么用
- 原文结论指出证据不足以推荐在全覆膜自膨式金属支架置入前常规行内镜下括约肌切开。
局限性
- 研究因无效提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) with fully covered self-expandable metal stent (FCSEMS) placement is the preferred approach for biliary drainage in patients with suspected distal malignant biliary obstruction (MBO). However, FCSEMS placement is associated with a high risk of post-ERCP pancreatitis (PEP). Endoscopic sphincterotomy prior to FCSEMS placement may reduce PEP risk. OBJECTIVE: To compare endoscopic sphincterotomy to no sphincterotomy prior to FCSEMS placement. DESIGN: This multicentre, randomised, superiority trial was conducted in 17 hospitals and included patients with suspected distal MBO. Patients were randomised during ERCP to receive either endoscopic sphincterotomy (sphincterotomy group) or no sphincterotomy (control group) prior to FCSEMS placement. The primary outcome was PEP within 30 days. Secondary outcomes included procedure-related complications and 30-day mortality. An interim analysis was performed after 50% of patients (n=259) had completed follow-up. RESULTS: Between May 2016 and June 2023, 297 patients were included in the intention-to-treat analysis, with 156 in the sphincterotomy group and 141 in the control group. After the interim analysis, the study was terminated prematurely due to futility. PEP did not differ between groups, occurring in 26 patients (17%) in the sphincterotomy group compared with 30 patients (21%) in the control group (relative risk 0.78, 95% CI 0.49 to 1.26, p=0.37). There were no significant differences in bleeding, perforation, cholangitis, cholecystitis or 30-day mortality. CONCLUSION: This trial found that endoscopic sphincterotomy was not superior to no sphincterotomy in reducing PEP in patients with distal MBO. Therefore, there was insufficient evidence to recommend routine endoscopic sphincterotomy prior to FCEMS placement. TRIAL REGISTRATION NUMBER: NL5130.
引用
- Onnekink AM, Gorris M, Bekkali NL, et al. Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial. Gut. 2025. PMID: 39389757. doi:10.1136/gutjnl-2024-332695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。